DanDrit Biotech signs deal with Saudi firm on MCV

24 April 2015

The Danish subsidiary of biotech firm DanDrit Biotech USA (OTCQB: DDRT), seeking to develop an approved vaccine for the treatment of colorectal cancer, has signed a partnership agreement with Saudi Arabia-based Riyadh Pharma. Financial terms of the agreement have not been disclosed.

This collaboration agreement advances DanDrit's goal to deliver an innovative portfolio of novel cell therapy therapeutics for conditions with a high unmet need. The specific aim of this agreement is to promote cooperation in the manufacturing and marketing of DanDrit's dendritic cell cancer vaccine, MelCancerVac (MCV), in the Kingdom's Riyadh Pharma factory. MCV is a dendritic cell vaccine designed to prevent relapse of colon cancer after standard therapy.

Riyadh Pharma will be responsible for the manufacturing of MCV in the Middle East. In addition, the two companies are committed to supply cancer vaccines by manufacturing in accordance with scientific standards and international quality standards applicable in this respect.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK